表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)治疗EGFR敏感突变的晚期非小细胞肺癌(NSCLC)疗效卓越。EGFR突变肺癌TKI应用的适应证已从二线到一线,能否从进展期一线进一步扩展到早中期辅助/新辅助,从延长晚期肺癌无进展生存期到提高可手术患者的治愈率是一个令人期待的研究方向。该文主要对EGFR-TKI在NSCLC围术期的治疗作用进展进行论述。 Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in the treatment of EGFR-sensitive mutations in advanced non-small cell lung cancer (NSCLC) with excellent results. The indications for the application of TKI for lung cancer with EGFR mutation have been from second line to first line, and whether it can be further extended from the advanced stage to early / mid-stage adjuvant / neoadjuvant can be achieved by prolonging the progression-free survival of advanced lung cancer to increasing the cure rate of operable patients Looking forward to the research direction. This article mainly discusses the progress of EGFR-TKI in NSCLC perioperative treatment.